PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer
A second BRAF and MEK inhibitor pair, encorafenib plus binimetinib, shrank tumours in three quarters of untreated and nearly half of previously treated patients with BRAF V600E lung cancer, giving a better-tolerated alternative to dabrafenib-trametinib.
Overview
Phase 2 study of 98 patients with BRAF V600E-mutant metastatic non-small-cell lung cancer, 59 treatment-naive and 39 previously treated, given encorafenib plus binimetinib.
Objective response was 75 percent in treatment-naive and 46 percent in previously treated patients, with median duration of response not reached and 16.7 months respectively; pyrexia was less common than with dabrafenib-trametinib.
- Objective response 75 percent (treatment-naive) and 46 percent (previously treated).
- Median duration of response 16.7 months in previously treated patients.
Encorafenib-binimetinib is approved for BRAF V600E lung cancer and offers a second targeted option, particularly for patients troubled by fever on dabrafenib-trametinib.
- Single-arm; no head-to-head comparison with dabrafenib-trametinib.
Similar pages
not linked directly; found by shared links- TrialPhase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung
Shares Binimetinib, BRAF V600E-mutant non-small-cell lung cancer, Encorafenib.
- TrialA Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Shares Binimetinib, Encorafenib.
- Key paperBEACON CRC: encorafenib and cetuximab with or without binimetinib in BRAF V600E-mutated colorectal cancer
Shares Binimetinib, Encorafenib.
- TrialAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
Shares Binimetinib, Encorafenib.
- Key paperCOLUMBUS: encorafenib plus binimetinib versus vemurafenib or encorafenib in BRAF-mutant melanoma
Shares Binimetinib, Encorafenib.
- TermBRAF V600E mutation
Shares PHAROS, BRAF V600E-mutant non-small-cell lung cancer.
- TrialCOLUMBUS
Shares Binimetinib, Encorafenib.
- TrialBEACON CRC
Shares Binimetinib, Encorafenib.